Skip to content
value.today

Reneo Pharmaceuticals, Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2014
Total raised
$94 M
3 rounds on record
Latest round
$47 M
Dec 2020
First round on record
Dec 2017
Today
Went public
See the company page

Reneo Pharmaceuticals, Inc. is listed today as OnKure Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Reneo Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$65 MPrivate placement after listing$50 to $250 million

Reneo Pharmaceuticals, Inc.: Private sale, Oct 2024

Investors in this round

20 investors had bought by the notice of Oct 21, 2024: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Reneo Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,250,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dylan Hartley · Executive Officer
  • Jason Leverone · Executive Officer
  • Nicholas Saccomano · Executive Officer, Director
  • Samuel Agresta · Executive Officer
  • Andrew Johm Phillips · Director
  • Edward T. Mathers · Director
  • Isaac M. Manke · Director
  • Michael G. Grey · Director
  • R. Michael Carruthers · Director
  • Valerie M. Jansen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeSci Capital, LLC (CRD 168404) · New York, New YorkSold in all US states
  • Leerlink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states
  • Evercore Group, L.L.C (CRD 42405) · New York, New YorkSold in all US states

Signed by Jason Leverone, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2024. Read the notice at the SEC.

equitySEC
Dec 2020$47 MNo. 3$10 to $50 million

Reneo Pharmaceuticals, Inc.: Raise no. 3, Dec 2020

Investors in this round

15 investors had bought by the notice of Dec 21, 2020: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Reneo Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$47 M of $95 M offered; $47 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alejandro Dorenbaum, M.D. · Executive Officer
  • Gregory Flesher · Executive Officer, Director
  • Mike Cruse · Executive Officer
  • Wendy Johnson · Executive Officer
  • Bali Muralidhar · Director
  • Ed Mathers · Director
  • Johan Kordel, Ph.D. · Director
  • Kenneth Harrison · Director
  • Lon Cardon, Ph.D. · Director
  • Michael Grey · Director
  • Niall O'Donnell, Ph.D. · Director
  • Stacey Seltzer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory Flesher, President and CEO. Source: SEC Form D, newest notice filed Dec 21, 2020. Read the notice at the SEC.

equitySEC
May 2019$25 MNo. 2$10 to $50 million

Reneo Pharmaceuticals, Inc.: Raise no. 2, May 2019

Investors in this round

9 investors had bought by the notice of May 14, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Reneo Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alejandro Dorenbaum, M.D. · Executive Officer
  • Niall O'Donnell, Ph.D. · Executive Officer, Director
  • Wendy Johnson · Executive Officer
  • Art Pappas · Director
  • Ed Mathers · Director
  • Johan Kordel, Ph.D. · Director
  • Lon Cardon, Ph.D. · Director
  • Michael Grey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold reflect the total shares offered and sold in a milestone closing of a previously disclosed equity financing of the Company.”

Signed by Niall O'Donnell, Ph.D., President and CEO. Source: SEC Form D, newest notice filed May 14, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$22 MNo. 1$10 to $50 million

Reneo Pharmaceuticals, Inc.: Raise no. 1, Dec 2017

Investors in this round

16 investors had bought by the notice of Jan 8, 2018: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Reneo Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $52 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Grey · Executive Officer, Director
  • Niall O'Donnell · Executive Officer, Director
  • Wendy Johnson · Executive Officer
  • Ed Mathers · Director
  • Scott Weiner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold includes amounts paid pursuant to conversion of indebtedness.”

Signed by Niall O'Donnell, President and CEO. Source: SEC Form D, newest notice filed Jan 8, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Reneo Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2024

That is all the official record says: Reneo Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Reneo Pharmaceuticals, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Reneo Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Nea 15 GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NEA Partners 15, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
New Enterprise Associates 15, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RiverVest Venture Fund III, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RiverVest Venture Fund III (Ohio), L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RiverVest Venture Fund IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding OnKure Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Reneo Pharmaceuticals, Inc.
NameRoleNamed in
Dylan HartleyExecutive officerOct 2024
Jason LeveroneExecutive officerOct 2024
Nicholas SaccomanoExecutive officerOct 2024
Samuel AgrestaExecutive officerOct 2024
Alejandro Dorenbaum, M.D.Executive officerDec 2020
Gregory FlesherExecutive officerDec 2020
Mike CruseExecutive officerDec 2020
Wendy JohnsonExecutive officerDec 2020
Niall O'Donnell, Ph.D.Executive officerMay 2019
Michael GreyExecutive officerJan 2018
Niall O'DonnellExecutive officerJan 2018
Andrew Johm PhillipsDirectorOct 2024
Edward T. MathersDirectorOct 2024
Isaac M. MankeDirectorOct 2024
Michael G. GreyDirectorOct 2024
Nicholas SaccomanoDirectorOct 2024
R. Michael CarruthersDirectorOct 2024
Valerie M. JansenDirectorOct 2024
Bali MuralidharDirectorDec 2020
Ed MathersDirectorDec 2020
Gregory FlesherDirectorDec 2020
Johan Kordel, Ph.D.DirectorDec 2020
Kenneth HarrisonDirectorDec 2020
Lon Cardon, Ph.D.DirectorDec 2020
Michael GreyDirectorDec 2020
Niall O'Donnell, Ph.D.DirectorDec 2020
Stacey SeltzerDirectorDec 2020
Art PappasDirectorMay 2019
Niall O'DonnellDirectorJan 2018
Scott WeinerDirectorJan 2018

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.